Our group has developed an intranasal therapy to deliver a pool of SOCS3 siRNA into the lungs of chronic asthmatic mice, leading to a decrease in lung eosinophilia as well as a significant reduction of AHR and mucous in the airways, which in turn improves chronicity and remodeling [14]. The gene discussed is SOCS3; the disease is medical procedure.